IWILFIN Trademark

Trademark Overview

On Wednesday, July 21, 2021, a trademark application was filed for IWILFIN with the United States Patent and Trademark Office. The USPTO has given the IWILFIN trademark a serial number of 90839565. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Monday, October 28, 2024. This trademark is owned by USWM, LLC. The IWILFIN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for the treatment and prevention of cancer; Pharmaceuticals for use in conjunction with multi-modal therapies for treatment of neuroblastoma
iwilfin

General Information

Serial Number90839565
Word MarkIWILFIN
Filing DateWednesday, July 21, 2021
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateMonday, October 28, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 24, 2022

Trademark Statements

Goods and ServicesPharmaceuticals for the treatment and prevention of cancer; Pharmaceuticals for use in conjunction with multi-modal therapies for treatment of neuroblastoma

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 19, 2024
Primary Code005
First Use Anywhere DateTuesday, January 16, 2024
First Use In Commerce DateTuesday, January 16, 2024

Trademark Owner History

Party NameUSWM, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressLouisville, KY 40241
Party NameUSWM, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressLouisville, KY 40241

Trademark Events

Event DateEvent Description
Monday, October 4, 2021ASSIGNED TO LIE
Saturday, July 24, 2021NEW APPLICATION ENTERED
Thursday, July 29, 2021TEAS VOLUNTARY AMENDMENT RECEIVED
Wednesday, September 22, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 5, 2021PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Thursday, April 14, 2022ASSIGNED TO EXAMINER
Friday, April 15, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, April 18, 2022LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, May 4, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 24, 2022PUBLISHED FOR OPPOSITION
Tuesday, May 24, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 19, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, January 5, 2023SOU TEAS EXTENSION RECEIVED
Thursday, January 5, 2023SOU EXTENSION 1 FILED
Thursday, January 5, 2023SOU EXTENSION 1 GRANTED
Saturday, January 7, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 29, 2023SOU TEAS EXTENSION RECEIVED
Thursday, June 29, 2023SOU EXTENSION 2 FILED
Thursday, June 29, 2023SOU EXTENSION 2 GRANTED
Saturday, July 1, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sunday, October 22, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sunday, October 22, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sunday, October 22, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, January 18, 2024SOU EXTENSION 3 GRANTED
Thursday, January 18, 2024SOU TEAS EXTENSION RECEIVED
Thursday, January 18, 2024SOU EXTENSION 3 FILED
Thursday, July 18, 2024USE AMENDMENT FILED
Thursday, July 18, 2024TEAS STATEMENT OF USE RECEIVED
Saturday, January 20, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 19, 2024STATEMENT OF USE PROCESSING COMPLETE
Monday, October 28, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Monday, October 28, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, September 20, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL

Related Keywords

iwilfin pharmaceuticals treatment therapies neuroblastoma modal conjunction prevention cancer multi